Deutsche Bank Aktiengesellschaft Increases Hims & Hers Health (NYSE:HIMS) Price Target to $16.00

Hims & Hers Health (NYSE:HIMS - Free Report) had its price objective lifted by Deutsche Bank Aktiengesellschaft from $14.00 to $16.00 in a research report sent to investors on Tuesday morning, Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a hold rating on the stock.

Other analysts also recently issued reports about the company. Canaccord Genuity Group began coverage on Hims & Hers Health in a report on Wednesday, April 10th. They issued a buy rating and a $20.00 target price for the company. Imperial Capital raised Hims & Hers Health from an in-line rating to an outperform rating and set a $16.00 price objective for the company in a report on Wednesday, February 28th. SVB Leerink assumed coverage on shares of Hims & Hers Health in a report on Monday, February 26th. They issued a market perform rating and a $10.00 target price on the stock. Piper Sandler increased their price target on shares of Hims & Hers Health from $11.00 to $13.00 and gave the stock a neutral rating in a research note on Tuesday. Finally, Leerink Partnrs restated a market perform rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $15.07.

Hims & Hers Health Stock Up 6.1 %

Hims & Hers Health stock traded up $0.71 during mid-day trading on Tuesday, hitting $12.36. The company had a trading volume of 25,676,533 shares, compared to its average volume of 5,076,590. Hims & Hers Health has a 1 year low of $5.65 and a 1 year high of $17.16. The business has a fifty day moving average of $14.04 and a 200 day moving average of $10.35. The stock has a market cap of $2.65 billion, a price-to-earnings ratio of -112.27 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm had revenue of $278.20 million for the quarter, compared to the consensus estimate of $270.37 million. During the same period last year, the firm posted ($0.05) EPS. The company's revenue was up 45.8% on a year-over-year basis. Equities analysts anticipate that Hims & Hers Health will post 0.11 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $15.65, for a total value of $39,171.95. Following the sale, the insider now directly owns 166,866 shares in the company, valued at $2,611,452.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Hims & Hers Health news, insider Soleil Boughton sold 2,503 shares of the company's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95. Following the transaction, the insider now directly owns 166,866 shares in the company, valued at $2,611,452.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Irene Becklund sold 2,747 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $12.08, for a total transaction of $33,183.76. Following the sale, the insider now owns 5,494 shares of the company's stock, valued at $66,367.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 736,191 shares of company stock valued at $9,733,700. 31.63% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $48,000. Belpointe Asset Management LLC acquired a new position in shares of Hims & Hers Health in the third quarter worth $76,000. EMC Capital Management lifted its position in shares of Hims & Hers Health by 80.0% in the third quarter. EMC Capital Management now owns 12,000 shares of the company's stock valued at $79,000 after acquiring an additional 5,332 shares in the last quarter. Certuity LLC acquired a new stake in shares of Hims & Hers Health during the fourth quarter valued at $109,000. Finally, Corton Capital Inc. purchased a new stake in Hims & Hers Health during the 3rd quarter worth about $122,000. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.